Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland

The implementation of pharmacogenetic testing into clinical practice has been a slow process so far. Here, we review the implementation of pre-treatment testing of dihydropyrimidine dehydrogenase gene (DPYD) risk variants to prevent early-onset fluoropyrimidine (FP)-related toxicity in cancer patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Begré, Ursina B. M., Jörger, Markus, Aebi, Stefan, Amstutz, Ursula, Largiadèr, Carlo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159275/
https://www.ncbi.nlm.nih.gov/pubmed/35662713
http://dx.doi.org/10.3389/fphar.2022.885259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159275/
https://www.ncbi.nlm.nih.gov/pubmed/35662713
http://dx.doi.org/10.3389/fphar.2022.885259

Ejemplares similares